Bioaffinity technologies - About the company
Bioaffinity technologies is a public company based in San Antonio (United States), founded in 2014. It operates as a Developer of IVD and targets cancer cells for therapeutics. Bioaffinity technologies has raised $9.05M in funding. The company has 35 active competitors, including 6 funded and 7 that have exited. Its top competitors include companies like Cytek Biosciences, Accuri Cytometers and FluoroFinder.
Company Details
Developer of IVD and targets cancer cells for therapeutics. The company design a platform for the detection and treatment of many cancers. The first product of the company CyPath is a bio label with a high affinity for cancer cells. This label technology allows cancer cells to fluoresce, leading to detection.
- Website
- bioaffinitytech.com
- Social
- Email ID
- *****@bioaffinitytech.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2014
Location
San Antonio, United States
Stage
Public
Total Funding
$9.05M in 6 rounds
Latest Funding Round
Investors
Ranked
2nd among 35 active competitors
Annual Revenue
$1M - $10M as on Dec 31, 2025
Employee Count
34 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Bioaffinity technologies
Bioaffinity technologies is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
BIOAFFINITY TECHNOLOGIES, INC. CIN: 1712762 , United States, Active | Mar 25, 2014 | $1M - $10M (As on Dec 31, 2025) | 65 (As on Jul 31, 2021) | - |
Bioaffinity technologies's IPO details
Bioaffinity technologies got listed on Sep 01, 2022.
Click here to take a look at Bioaffinity technologies's IPO in detail
Sign up to download Bioaffinity technologies' company profile
Bioaffinity technologies's funding and investors
Bioaffinity technologies has raised a total funding of $9.05M over 6 rounds. Its first funding round was on Mar 09, 2017. Bioaffinity technologies has 1 institutional investor.
Here is the list of recent funding rounds of Bioaffinity technologies:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 14, 2025 | 1968673 | Post IPO | 4184337 | 2749767 | 5751638 | 4722112 |
Aug 02, 2024 | 7415696 | Post IPO | 1217869 | 3735120 | 3756921 | 1346068 |
Mar 06, 2024 | 9875061 | Post IPO | 1918600 | 2024558 | 9540740 | 9250447 |
Access funding benchmarks and valuations. Sign up today!View details of Bioaffinity technologies's funding rounds and investors
Bioaffinity technologies' founders and board of directors
Founder? Claim ProfileBioaffinity technologies' employee count trend
Bioaffinity technologies has 34 employees as of Sep 26. Here is Bioaffinity technologies's employee count trend over the years:
Uncover Bioaffinity technologies' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Bioaffinity technologies's Competitors and alternates
Top competitors of Bioaffinity technologies include Cytek Biosciences, Accuri Cytometers and FluoroFinder. Here is the list of Top 10 competitors of Bioaffinity technologies, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Cytek Biosciences 2014, San Francisco (United States), Public | Manufacturer of flow cytometry systems for research applications | $144M | 67/100 | |
2nd | Bioaffinity technologies 2014, San Antonio (United States), Public | Developer of IVD and targets cancer cells for therapeutics | $9.05M | 49/100 | |
3rd | Accuri Cytometers 2004, Ann Arbor (United States), Acquired | Cell Analysis Flow Cytometers | $30.9M | 45/100 | |
4th | FluoroFinder 2008, Westminster (United States), Series A | Design and search tool to find the best flow cytometry products for the panel | $4.66M | 40/100 | |
5th | IntelliCyt 2006, Albuquerque (United States), Acquired | Life science company providing innovative solutions for research and biopharmaceutical manufacturing | $13.8M | 40/100 | |
6th | Amphasys 2012, Lucerne (Switzerland), Funding Raised | Developer of label-free technology for pollen viability analysis | - | 39/100 | |
7th | BennuBio 2018, Albuquerque (United States), Series A | Provider of flow cytometry equipment and services | $7.82M | 39/100 | |
8th | _1556878212790.png?devicePixelRatio=2&height=30&width=30){kind=logo} NanoFCM 2014, Nottingham (United Kingdom), Unfunded | Developer of instruments for single-molecule fluorescence detection | - | - | 39/100 |
9th |  Lucendi 2016, Los Angeles (United States), Series A | AI-enabled smart measurement systems using computational microscopy technology for micro-object characterization | $2M | 38/100 | |
10th | ACEA Biosciences 2002, San Diego (United States), Acquired | Developer of instruments for life science research | $37.9M | 38/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Bioaffinity technologies's competitors? Click here to see the top ones
Bioaffinity technologies's Investments and acquisitions
Bioaffinity technologies has made no investments or acquisitions yet.
Reports related to Bioaffinity technologies
Here is the latest report on Bioaffinity technologies's sector:
News related to Bioaffinity technologies
Filter this listMedia has covered Bioaffinity technologies for a total of 38 events in the last 1 year, 13 of them have been about company updates and 2 about partnerships.
•
bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026Business Wire•Oct 15, 2026•Bioaffinity technologies
•
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct FinancingPR Newswire•Oct 08, 2026•WallachBeth Capital, Bioaffinity technologies
•
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026Business Wire•Oct 06, 2026•Bioaffinity technologies
•
bioAffinity Technologies and Pictor Partner for Asthma and COPD DiagnosticsMedical Product Outsourcing•Oct 01, 2026•Pictor, Bioaffinity technologies
•
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual ConferenceBusiness Wire•Sep 22, 2026•Bioaffinity technologies
•
BioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath(R) Lung Noninvasive Lung Cancer DiagnosticBusiness Wire•Sep 17, 2026•Bioaffinity technologies
•
bioAffinity Technologies Regains Compliance with Nasdaq Listing RequirementsBusiness Wire•Sep 09, 2026•Bioaffinity technologies
•
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer SurvivorsBusiness Wire•Sep 01, 2026•Bioaffinity technologies
•
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® LungBusiness Wire•Aug 18, 2026•Bioaffinity technologies
•
Bioaffinity Technologies Pricing $4 Million Private PlacementInvesting•Aug 13, 2026•Bioaffinity technologies, Nasdaq, WallachBeth Capital
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Bioaffinity technologies
Explore our recently published companies
- United Fortune - Unfunded company
- Initiative Chronische Wunden - Germany based, 2002 founded, Unfunded company
- Clomr - Pleasanton based, 2025 founded, Unfunded company
- Market&Measure - Unfunded company
- Time To Sign Off - France based, Unfunded company
- Altilis Nutrition Animale - Saint-Denis-de-Pile based, 1980 founded, Unfunded company
